Mothaffar F. Rimawi, MD
Precision medicine has become essential in delivering optimal and individualized care for patients with HER2-positive breast cancer.
Rimawi, associate professor, Baylor College of Medicine, medical director and director of clinical research at Baylor's Lester and Sue Smith Breast Center and the Smith Clinic/ Ben Taub Hospital, and co-leader of the breast program at Baylor's Dan L. Duncan Cancer Center, discussed the significance of precision medicine in HER2-positive breast cancer, as well as the possible role of immunotherapy for this specific population.
OncLive: What is the importance of precision medicine in HER2-positive breast cancer?
[At SABCS] I discussed the research that is shedding light on HER2-positive breast cancer, including mechanisms of resistance, sensitivity, and the efforts to tailor treatments to the individual patient.
... to read the full story